Suggested remit: To appraise the clinical and cost effectiveness of daprodustat within its marketing authorisation for treating anaemia in adults with chronic kidney disease.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2022
ID number 3987

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors GlaxoSmithKline (Jesduvrog,
Others Department of Health and Social Care
  NHS England
  NHS Nottingham and Nottinghamshire
  NHS Salford CCG
  Welsh Government
Patient carer groups Kidney Care UK
  Kidney Research UK
  National Kidney Federation
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Anaemia Nurse Specialist Association
  Association of Renal Technologists
  British Association of Urological
  British Association of Urological
  British Committee for Standards in
  British Geriatrics Society
  British Society for Haematology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  The Urology Foundation
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
  UK Kidney Association
  UK Renal Pharmacy Group
Assessment group Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Amgen (darbepoetin alfa)
  Pfizer (epoetin zeta)
  Janssen (epoetin alfa)
  Roche (epoetin beta, methoxy
  polyethylene glycol-epoetin beta)
  Astellas Pharma Ltd (roxadustat)
General commentators All Wales Therapeutic and Toxicology
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services
  and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products
  Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services
  Welsh Kidney Patients Association
Relevant research groups Cochrane Kidney and Transplant Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
15 June 2022 Invitation to participate
28 January 2022 - 25 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual